HRSA Announces 340B Enrollment Flexibilities in Fire-Ravished New Mexico

HRSA has announced 340B program enrollment flexibilities in New Mexico, which is coping with the biggest wildfire in state history.

The U.S. Health Resources and Services Administration (HRSA) yesterday announced 340B program enrollment flexibilities in New Mexico due to the declaration of a public health emergency in the state.

Please Login or Become a

Read More »

Mallinckrodt Is the Third Drug Company This Month to Announce Refunds for 340B Overcharges

Mallinckrodt's SpecGx subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.

Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.

Please Login or Become a Paid Subscriber to View this

Read More »

Breaking News

HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months

HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.

The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each

Read More »

HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves

The "Man Controlling Trade" statute outside the FTC's Washington, D.C., headquarters. HIV/AIDS clinics recently submitted comments to the commission about PBMs' business practices.

Pharmacy benefit managers (PBMs) should be stopped from usurping 340B drug discounts from HIV/AIDS clinics and other safety-net providers, Ryan White Clinics for 340B Access (RWC-340B) told the U.S. Federal Trade Commission (FTC) last week.

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.

Please Login or Become a Paid

Read More »

Today Is Last Day for Some Hospitals to File Paperwork for 340B Reinstatement

Today is the last day for hospitals that have lost their 340B eligibility during the COVID-19 pandemic to file paperwork to be reinstated to the drug discount program.

Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.

Please Login or Become a

Read More »

Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021

Astellas is issuing 340B covered entities refunds for overcharges on Xtandi and Myrbetriq for the period from Q3 2020 through Q2 2021.

Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content